Samsung C&T (028260) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
23 Jun, 2026Executive summary
Achieved consolidated sales of KRW 9.74 trillion in Q1 2025, down 9.8% year-over-year, with net profit of KRW 937 billion, up 14% year-over-year and 43% sequentially.
Operating profit rose to KRW 724.4 billion, up 1.7% year-over-year and 14% sequentially, with an improved operating margin of 7.4%.
Construction and trading comprised the largest revenue shares, while Bio and T&I segments offset declines in E&C, Fashion, and Leisure.
Maintained strong liquidity with cash and cash equivalents at KRW 3.26 trillion as of March 31, 2025.
Financial highlights
Gross profit increased to KRW 1,753 billion, up 6.3% year-over-year; gross margin for Q1 2025 was 18.0%.
Operating income was KRW 724.4 billion, up from KRW 648.6 billion in Q1 2024.
Net income attributable to owners was KRW 732.8 billion, up from KRW 728.0 billion in Q1 2024.
Net cash position at KRW 992 billion, down from KRW 1,262 billion at end of 2024.
Total assets at KRW 62.46 trillion, equity at KRW 38.33 trillion.
Outlook and guidance
Targeting 22GW solar pipeline and $100 million in asset disposal gains in 2025 for T&I.
Continued focus on landmark housing projects, SMR expansion in Europe, and high-value projects.
Bio segment expects further growth with Plant 5 operations, large CMO contracts, and global expansion.
Dividend policy targets 60–70% of affiliate dividend income, with a minimum annual payout of KRW 2,000 per share through 2025.
Latest events from Samsung C&T
- H1 2024 net profit reached ₩1.3 trillion on ₩21.8 trillion revenue, led by bio and construction.028260
Q2 202423 Jun 2026 - Nine-month revenue reached ₩32.1T, with strong bio and F&B growth and stable capital structure.028260
Q3 202423 Jun 2026 - H1 2025 revenue KRW 19.76T, net income KRW 1.09T, strong bio/construction, Bio outlook raised.028260
Q2 202523 Jun 2026 - Nine-month revenue hit KRW 29.91 trillion, led by bio growth and strong liquidity.028260
Q3 202523 Jun 2026 - Q1 2026 profit and revenue rose, driven by trading and bio, with strong cash flow and liquidity.028260
Q1 202622 Jun 2026 - Net profit rose 15% year-over-year in 4Q 2024, driven by Bio and T&I growth.028260
Q4 202410 Mar 2026 - Net profit surged YoY in 4Q25, with Bio and E&C driving growth and a positive 2026 outlook.028260
Q4 202510 Mar 2026